БЕСПОНЗА
Active Ingredient: Inotuzumab ozogamicin
Product Overview
About БЕСПОНЗА
БЕСПОНЗА is a prescription medication containing the active ingredient Inotuzumab ozogamicin, a monoclonal antibody-drug conjugate used in the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Key Benefits & Uses
- Treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)
- Monotherapy for adult patients with relapsed or refractory B-cell precursor ALL
- Administered intravenously every 3 weeks for a maximum of 6 cycles
Active Ingredient & Action
Inotuzumab ozogamicin works by binding to CD22, a protein expressed on the surface of B cells, and delivering a cytotoxic agent, calicheamicin, directly to the cancer cells. This targeted approach helps minimize harm to healthy cells and tissues.
Important Notes
БЕСПОНЗА is available only through a restricted distribution program. Patients and healthcare providers must enroll in the program to obtain the medication. It is essential to follow the recommended dosing schedule and to monitor patients for potential side effects, including infusion-related reactions, hematologic toxicity, and hepatotoxicity.
Visitor ratings
Help others by rating how useful this product page is.
No ratings yet — be the first.